ArticleJournal of translational medicine2025
Lactylation-induced ALKBH5 targets RNF123 to worsen retinal Müller cell activation through PKM2-regulated Glycolysis in diabetic retinopathy.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The crosstalk between RNA m6A modification and protein lactylation: emerging insights into tumor progression.Oncogene · 2026Review
- Interplay between N6-methyladenosine RNA methylation and protein lactylation: a novel crosstalk linking metabolism and epigenetic regulation in human diseases.Journal of translational medicine · 2026Review
- The N6-Methyladenosine RNA Demethylase AlkB Homolog 5 (ALKBH5) in Metabolic Diseases: Molecular Mechanisms and Pharmacological Implications-A Review.Biomolecules · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundUbiquitin ligase RNF123 affects a variety of pathological processes, but little is known about its regulatory mechanism. This study defined the regulatory mechanisms of RNF123 in Müller cell activation in diabetic retinopathy (DR).
methodsRNF123 expression was analyzed in the retina of DR patients and diabetic mice. Müller cell line MIO-M1 treated with high glucose (HG) was used to explore the upstream and downstream signal regulation mechanism of RNF123 in vitro. Müller cell activation and glycolysis were indicated using cell viability, cell migration, levels of inflammatory factors, GFAP and GS expression levels, extracellular acidification rate and lactate production. Diabetic rat models induced by streptozotocin were used to investigate the critical role of the RNF123-glycolytic axis in DR in vivo.
resultsRNF123 expression was decreased in the retina of DR patients, diabetic mice and HG-stimulated Müller cells. HG-induced pathological activation of MIO-M1 cells, manifested as increased viability, migration, inflammatory factors production and GFAP expression and decreased GS expression, and also increased glycolysis. These pathological changes were reversed by RNF123 overexpression. Glycolysis inhibition by 2-DG reversed RNF123 knockdown-induced Müller cell activation. RNF123 targeting ubiquitination of PKM2 in HG-induced MIO-M1 cell activation. HG-induced downregulation of RNF123 was regulated by ALKBH5 and IGF2BP1-mediated m6A modification. HG-induced upregulation of ALKBH5 was mediated by histone lactylation. The lactate-ALKBH5-RNF123-PKM2 regulatory axis was involved in HG-induced Müller cell activation and retinal damage of the diabetic rats.
conclusionsLactate increases glycolysis through the ALKBH5-RNF123-PKM2 signaling axis to form a feedback regulation mechanism to activate Müller cells, which is an important pathological mechanism of DR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.